ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.

If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

To join the ARS Pharmaceuticals class action, go to https://rosenlegal.com/cases/ars-pharmaceuticals-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

According to the lawsuit, defendants provided investors with material information concerning ARS Pharmaceuticals' expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Defendants' statements included, among other things, confidence that this coverage would begin on July 1, 2026, and be in place for the summer and back-to-school allergy seasons.

According to the lawsuit, defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the expected timeline for the expanded insurance coverage for neffy through CVS Caremark. This caused shareholders to purchase ARS Pharmaceuticals securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the ARS Pharmaceuticals class action, go to https://rosenlegal.com/cases/ars-pharmaceuticals-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.